Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 56879. Отображено 100.
19-01-2012 дата публикации

Enhanced Natural Colors

Номер: US20120014934A1
Автор: Jeffrey M. Wuagneux, Paul Altaffer, Pi-Yu Hsu
Принадлежит: RFI LLC

A natural color is concentrated to intensify color range and to provide useful amounts of one or more of anti-oxidant, nutritional, and anti-inflammatory compounds derived from one or more pigment sources. In a preferred embodiment, the pigment source is a fruit, a vegetable, a legume, a spice, algae, or a combination thereof.

Подробнее
Номер записи: 1
02-02-2012 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: US20120027796A1
Автор: David Butler, Jayaprakash K. Narayanannair, Kallanthottathil G. Rajeev, Laxmab Eltepu, Muthiah Manoharan, Muthusamy Jayaraman
Принадлежит: Alnylam Pharmaceuticals Inc

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures: (Formula (I) or (XXXV)).

Подробнее
Номер записи: 2
09-02-2012 дата публикации

Tyrosine kinase receptor tyro3 as a therapeutic target in the treatment of cancer

Номер: US20120034167A1
Автор: François RADVANYI, Isabelle Bernard-Pierrot, Nicolas Stransky, Yves Allory
Принадлежит: Assistance Publique Hopitaux de Paris APHP, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, INSTITUT CURIE, Universite Paris Est Creteil Paris 12

The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.

Подробнее
Номер записи: 3
09-02-2012 дата публикации

Glycolipids as treatment for disease

Номер: US20120035120A1
Автор: Shawn Defrees
Принадлежит: Seneb Biosciences Inc

This invention provides compounds, compositions, and methods for treating a disorder selected from cancer, hyperinsulinemia, hypoglycemia, hyperinsulinemia with hypoglycemia, atypical Parkinson's disease, Huntington's disease, multiple systems atrophy, GM3 synthase deficiency, GM2 synthase deficiency or tauopathy.

Подробнее
Номер записи: 4
09-02-2012 дата публикации

Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders

Номер: US20120035243A1
Автор: Eric Olson, Eva Van Rooij
Принадлежит: University of Texas System

The present invention provides a method of treating or preventing cardiac disorders in a subject in need thereof by inhibiting the expression or function of both miR-499 and miR-208 in the heart cells of the subject. In particular, specific protocols for administering inhibitors of the two miRNAs that achieve efficient, long-term suppression are disclosed. In addition, the invention provides a method for treating or preventing musculoskeletal disorders in a subject in need thereof by increasing the expression or activity of both miR-208 and miR-499 in skeletal muscle cells of the subject.

Подробнее
Номер записи: 5
23-02-2012 дата публикации

Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family

Номер: US20120046345A1
Автор: Joseph Collard, Olga Khorkova Sherman
Принадлежит: OPKO CURNA LLC

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Dystrophin family, in particular, by targeting natural antisense polynucleotides of Dystrophin family. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DMD family.

Подробнее
Номер записи: 6
08-03-2012 дата публикации

Nutritional composition inducing a postprandial endocrine response

Номер: US20120058938A1
Автор: Mirian Lansink, Robert Johan Joseph Hageman
Принадлежит: Nutricia NV

The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body. In particular, the invention concerns the use of a nutritional composition for the treatment of a disorder, which is mediated by a postprandial endocrine or neurological response in a human body, wherein the nutritional composition comprises one or more of a specific protein fraction, a specific carbohydrate fraction and a specific nutritional fiber fraction.

Подробнее
Номер записи: 7
08-03-2012 дата публикации

Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor

Номер: US20120059462A1
Автор: Vernon G. Wong
Принадлежит: Allergan Inc

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

Подробнее
Номер записи: 8
15-03-2012 дата публикации

Test agent for visceral obesity and use thereof

Номер: US20120066777A1
Автор: Atsunori Kashiwagi, Hiroshi Maegawa, Masatomo Rokushima, Minoru Ikeda, Minoru Suzuki, Shiro Maeda, Tatsuya Takahashi, Tohru Tani, Yoshihiro Kawamura
Принадлежит: RIKEN Institute of Physical and Chemical Research, Shiga University of Medical Science NUC, Shionogi and Co Ltd

Disclosed are: a method for detecting (diagnosing) visceral obesity in a subject; a test agent useful for the method; a method for searching for a substance that can be used as an active ingredient for ameliorating visceral obesity; and an ameliorating agent for visceral obesity or a medicinal agent for preventing a metabolic disease developed as a result of the progression of visceral obesity. As the test agent, a polynucleotide which comprises at least 15 nucleotides and can hybridize with a nucleotide sequence for coiled-coil domain containing protein 3 (CCDC3) gene or a nucleotide sequence complementary to the nucleotide sequence under stringent conditions or an antibody capable of recognizing CCDC3 protein is used.

Подробнее
Номер записи: 9
22-03-2012 дата публикации

Estrogen receptor modulators and uses thereof

Номер: US20120071535A1
Автор: Andiliy G. Lai, Celine Bonnefous, Jackaline D. Julien, Johnny Y. Nagasawa, Mehmet Kahraman, Nicholas D. Smith, Steven P. Govek
Принадлежит: Aragon Pharmaceuticals Inc

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Подробнее
Номер записи: 10
29-03-2012 дата публикации

Use of Toll-like receptor-9 agonists, Toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of Toll-like receptor-4-associated disorders

Номер: US20120077868A1
Автор: David J. Hackam
Принадлежит: Individual

The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.

Подробнее
Номер записи: 11
12-04-2012 дата публикации

Methods for distributing agents to areas of brain

Номер: US20120087869A1
Автор: Deepak Ramesh Thakker, Greg Stewart, Lisa L. Shafer
Принадлежит: MEDTRONIC INC

Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.

Подробнее
Номер записи: 12
12-04-2012 дата публикации

Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations

Номер: US20120088726A1
Автор: Annalisa Sforzini, Carla Caramella, Giuseppe Bottoni, Giuseppe Claudio Viscomi, Mascia Federici, Paola Maffei, Silvia Rossi
Принадлежит: Alfa Wasserman SpA

Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients.

Подробнее
Номер записи: 13
19-04-2012 дата публикации

Hcv vaccines and methods for using the same

Номер: US20120093863A1
Автор: Amir S. Khan, David B. Weiner, Jian Yan, Krystle LANG, Ruxandra Draghia-Akli
Принадлежит: Inovio Pharmaceuticals Inc, University of Pennsylvania Penn

Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.

Подробнее
Номер записи: 14
19-04-2012 дата публикации

Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof

Номер: US20120094900A1
Автор: Emma Ito, Fei-Fei Liu, Inki Kim
Принадлежит: UNIVERSITY HEALTH NETWORK

There is provided herein methods, compounds and methods for identifying compounds, for sensitizing a subject with cancer to a cancer therapy by inhibiting or down-regulating UROD.

Подробнее
Номер записи: 15
19-04-2012 дата публикации

Nutraceutical Composition and Methods for Preventing or Treating Multiple Sclerosis

Номер: US20120094950A1
Автор: Javier Ochoa-Reparaz, Lloyd H. Kasper
Принадлежит: Dartmouth College

The present invention embraces nutraceutical compositions containing isolated Bacteroides fragilis capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.

Подробнее
Номер записи: 16
19-04-2012 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: US20120095075A1
Автор: David Butler, Kallanthottathil G. Rajeev, Laxman Eltepu, Muthiah Manoharan, Muthusamy Jayaraman, Narayanannair K. Jayaprakash
Принадлежит: Alnylam Pharmaceuticals Inc

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure:

Подробнее
Номер записи: 17
03-05-2012 дата публикации

Particulate composition and pharmaceutical composition containing the same

Номер: US20120107377A1
Автор: Atsushi Ishii, Yasuki Kato
Принадлежит: NanoCarrier Co Ltd

The present invention provides a particulate composition containing: block copolymer units being arranged radially with hydrophobic polymer-chain segments radially inside and hydrophilic polymer-chain segments radially outside; and a charged lipid which carries a charge opposite to the charge of a drug to be encapsulated, the charged lipid being attracted to the hydrophobic polymer-chain segment. In this particulate composition, the drug is retained within the particle via electrostatic binding with the charged lipid, whereby the outer surface of the particle is prevented from being charged to attract a substance which has a charge opposite to that of the charged lipid.

Подробнее
Номер записи: 18
10-05-2012 дата публикации

Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Номер: US20120114671A1
Автор: Joan Seoane Suarez, José BASELGA TORRES, Silvia Penuelas Prieto
Принадлежит: Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR, Institucio Catalana de Recerca i Estudis Avancats ICREA

The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.

Подробнее
Номер записи: 19
10-05-2012 дата публикации

Peptide/particle delivery systems

Номер: US20120114759A1
Автор: Aleksander S. Popel, Joel Chaim Sunshine, Jordan Jamieson Green, Kristen Lynn Kozielski, Ron B. Shmueli, Stephany Yi Tzeng
Принадлежит: JOHNS HOPKINS UNIVERSITY

Polymeric nanoparticles, microparticles, and gels for delivering cargo, e.g., a therapeutic agent, such as a peptide, to a target, e.g., a cell, and their use for treating diseases, including angiogenesis-dependent diseases, such as age-related macular degeneration and cancer, are disclosed. Methods for formulating, stabilizing, and administering single peptides or combinations of peptides via polymeric particle and gel delivery systems also are disclosed.

Подробнее
Номер записи: 20
10-05-2012 дата публикации

Surgical compositions for reducing the incidence of adhesions

Номер: US20120115810A1
Автор: Colin Brown
Принадлежит: Individual

A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulation containing the polysaccharide dextrin.

Подробнее
Номер записи: 21
10-05-2012 дата публикации

Pharmaceutical agent for preventing cell death

Номер: US20120115927A1
Автор: Futoshi Shibasaki, Li Chen
Принадлежит: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE

Disclosed is a pharmaceutical agent for preventing cell death. The occurrence of cell death can be prevented by inhibiting the function of Int6 protein in an affected area. Then, a pharmaceutical agent comprising a substance capable of inhibiting the function of Int6 protein is prepared. The pharmaceutical agent can be used for preventing cell death.

Подробнее
Номер записи: 22
10-05-2012 дата публикации

Anti-cancer agent, method for inducing apoptosis of cancer cells, and method for screening for anti-cancer agent

Номер: US20120115935A1
Автор: Naohisa Tomosugi, Yasuhito Ishigaki
Принадлежит: Individual

Disclosed is an anti-cancer agent which can inhibit the progression of cell cycle in the M phase, unlike taxane anti-cancer agents. The anti-cancer agent comprises a compound capable of inhibiting specifically the expression and/or functions of RBM8A depicted in SEQ ID NO: 1, Magoh depicted in SEQ ID NO: 3 or an isoform thereof. The anti-cancer agent can inhibit the expression and/or functions of RBM8A or Magoh in cancer cells to terminate the cell cycle in the M phase, thereby inhibiting the proliferation of the cells. Therefore, the anti-cancer agent can inhibit the proliferation of cancer cells and induce the apoptosis of cancer cells, leading to the cure of cancer.

Подробнее
Номер записи: 23
17-05-2012 дата публикации

Nucleic acid ligands to ll37

Номер: US20120121533A1
Автор: George W. Jackson
Принадлежит: Biotex Inc

The present invention is directed to nucleic acid ligands to LL37, methods for producing said nucleic acid ligands, and methods for utilizing said nucleic acid ligands. In one exemplary embodiment, for example, this invention relates to nucleic acid ligands exhibiting high specific binding affinity to LL37 peptides, precursors and/or portions thereof. Further, the nucleic acid ligands may bind competitively with native ligands of LL37 and may also inhibit and/or interfere with LL37 function, such as by binding to LL37.

Подробнее
Номер записи: 24
17-05-2012 дата публикации

METHODS AND COMPOSITIONS FOR REDUCING TARGET GENE EXPRESSION USING COCKTAILS OF siRNAS OR CONSTRUCTS EXPRESSING siRNAS

Номер: US20120122217A1
Автор: David Brown, Lance P. Ford, Rich Jarvis
Принадлежит: APPLIED BIOSYSTEMS LLC

The present invention concerns methods and compositions involving the production or generation of siRNA mixtures or pools capable of triggering RNA-mediated interference (RNAi) in a cell. Compositions of the invention include kits that include reagents for producing or generating siRNA pools. The present invention further concerns methods using polypeptides with RNase III activity for generating siRNA mixtures or pools that effect RNAi, including the generation of a number of RNA molecules to the same target gene.

Подробнее
Номер записи: 25
24-05-2012 дата публикации

Transcriptome Transfer Produces Cellular Phenotype Conversion

Номер: US20120129261A1
Автор: Jai-Yoon Sul, James Eberwine, Tai Kyung Kim, Vickas Patel
Принадлежит: University of Pennsylvania Penn

The present invention includes methods for effecting phenotype conversion in a cell by transfecting the cell with phenotype-converting nucleic acid. Expression of the nucleic acids results in a phenotype conversion in the transfected cell. Preferably the phenotype-converting nucleic acid is a transcriptome, and more preferably an mRNA transcriptome.

Подробнее
Номер записи: 26
24-05-2012 дата публикации

dsRNA For Treating Viral Infection

Номер: US20120129913A1
Автор: Jason Borawski, Larry Alexander Gaither, Mark Aron Labow
Принадлежит: NOVARTIS AG

The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propogation of positive stranded RNA viruses in and between cells.

Подробнее
Номер записи: 27
24-05-2012 дата публикации

Detection and treatment of autoimmune disorders

Номер: US20120130350A1
Автор: Anne M. Stevens, Neelufar Mozaffarian
Принадлежит: Seattle Childrens Hospital

Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a PD1 ligand.

Подробнее
Номер записи: 28
31-05-2012 дата публикации

Compositions containing mixtures of fermentable fibers

Номер: US20120135957A1
Автор: Annick Bernalier, Béatrice MORIO, Christian Fougnies, Heidi Jacobs, Veronique Coxam, Yann Dugenet
Принадлежит: COSUCRA GROUPE WARCOING SA, DF3 SAS

The present invention relates to synergistic compositions comprising mixtures of fermentable fibers. The present invention specifically relates to composition comprising inulin and arabinoxylan for use in reducing, preventing and/or treating inflammation, wherein said arabinoxylan is partially hydrolyzed arabinoxylan and wherein the ratio of said inulin to said arabinoxylan and/or partially hydrolyzed arabinoxylan is between 65%/35% by weight and 90%/10% by weight.

Подробнее
Номер записи: 29
31-05-2012 дата публикации

Carbohydrate conjugates as delivery agents for oligonucleotides

Номер: US20120136042A1
Автор: Kallanthottathil G. Rajeev, Martin Maier, Muthiah Manoharan, Narayanannair K. Jayaprakash
Принадлежит: Alnylam Pharmaceuticals Inc

The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula (I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

Подробнее
Номер записи: 30
07-06-2012 дата публикации

Nutritional supplement

Номер: US20120141447A1
Автор: Ford D. Albritton, Iv
Принадлежит: Individual

A nutritional supplement for inhibiting sensorineural hearing loss includes from about 0.25 to about 6.0 wt. % thiamin, from about 0.1 to about 10 wt. % pyridoxiyl-5-phosphate, from about 0.01 to about 10 wt. % folic acid, from about 0.025 to about 4.0 wt. % hydroxycobalamin, from about 1 to about 7 wt. % magnesium, from about 0.25 to about 6.0 wt. % zinc, from about 0.001 to about 0.02 wt. % selenium, from about 0.1 to about 10 wt. % manganese, from about 5 to about 50 wt. % ginger root P.E. 4:1., from about 5 to about 40 wt. % citrus bioflavonoids, from about 2.5 to about 40 wt. % 1-cystine, from about 5 to about 40 wt. % n-acetlyl-1-carnitine, from about 1 to about 40 wt. % alpha lipoic acid, from about 1 to about 40 wt. % coenzyme Q10, from about 1 to about 40 wt. % green tea extract, and from about 1 to about 60 wt. % resveratrol.

Подробнее
Номер записи: 31
07-06-2012 дата публикации

Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous System

Номер: US20120141456A1
Автор: Kenneth J. Rhodes, R. Blake Pepinsky, Sha Mi
Принадлежит: BIOGEN IDEC MA INC

The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.

Подробнее
Номер записи: 32
07-06-2012 дата публикации

Use of pkc isozymes for diagnosis and treatment of neuroblastoma

Номер: US20120141498A1
Автор: Mildred E. Acevedo-Duncan, Rekha S. Patel
Принадлежит: UNIVERSITY OF SOUTH FLORIDA, US Department of Veterans Affairs VA

The present invention pertains to the use of PKC-epsilon (PKC-ε), PKC-delta (PKC-δ), PKC-eta, and/or PKC-theta as biomarker(s) for prediction and/or detection of neuroblastoma, as well as therapeutic targets for treatment of neuroblastoma.

Подробнее
Номер записи: 33
21-06-2012 дата публикации

Cationic oil-in-water emulsions

Номер: US20120156251A1
Автор: Andrew Geall, Derek O'Hagan, Luis Brito, Manmohan Singh
Принадлежит: Individual

This invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are particularly suitable for delivering nucleic acid molecules (such as an RNA molecule encoding an antigen) to cells and formulating nucleic acid-based vaccines.

Подробнее
Номер записи: 34
21-06-2012 дата публикации

Minimal tissue attachment implantable materials

Номер: US20120157673A1
Автор: Constance Ace, Gonzalo Serafica, Jeremy Harris
Принадлежит: Xylos Corp

A method for minimizing tissue adhesion at an injured site is provided, the method comprising applying a biocellulose material to the injured site, whereby the adhesion of the tissues at the injured site is minimized, wherein the biocellulose material is at least partially dehydrated. Another embodiment provides an implantable material, which effectively prevents cell adhesion and has desirable mechanical properties.

Подробнее
Номер записи: 35
28-06-2012 дата публикации

Use of dietary fibres against muscle wasting

Номер: US20120165243A1
Автор: Adrianus Lambertus Bertholdus Van Helvoort, Marchel Gorselink, Robert Johan Joseph Hageman
Принадлежит: Nutricia NV

A composition nutritional containing dietary fibres is useful for the treatment of muscle wasting, if the dietary fibre comprise at least 30 wt. % of galacto-oligosaccharides or other oligosaccharides having mainly anhydropyranose units, and having a chain length of 3-10 units. The composition may further contain other oligo- or polysaccharides, especially polysaccharides having a majority of anhydrofuranose units.

Подробнее
Номер записи: 36
28-06-2012 дата публикации

Antisense oligonucleotides that target a cryptic splice site in ush1c as a therapeutic for usher syndrome

Номер: US20120165389A1
Автор: Michelle L. HASTINGS
Принадлежит: Individual

The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.

Подробнее
Номер записи: 37
05-07-2012 дата публикации

Methods and materials for modulating deubiquitinases and ubiquitinated polypeptides

Номер: US20120171192A1
Автор: Jian Yuan, Zhenkun Lou
Принадлежит: Mayo Foundation for Medical Education and Research

This document relates to methods and materials involved in modulating deubiquitinases (e.g., USP10 polypeptides) and/or ubiquitinated polypeptides (e.g., tumor suppressor polypeptides or mutant versions of tumor suppressor polypeptides). For example, methods and materials for increasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for decreasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for stabilizing tumor suppressor polypeptides (e.g., wild-type p53 polypeptides), methods and materials for de-stabilizing mutant versions of tumor suppressor polypeptides (e.g., mutant p53 polypeptides), and methods and materials for reducing cancer cell proliferation, increasing cancer cell apoptosis, and/or treating cancer (e.g., cancers having reduced levels of wild-type p53 polypeptides or cancers having increased levels of mutant p53 polypeptides) are provided. This document also provides methods and materials for identifying agonists or antagonists of USP10 polypeptide mediated stabilization of p53 polypeptides.

Подробнее
Номер записи: 38
05-07-2012 дата публикации

In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages

Номер: US20120172412A1
Автор: Andrei V. Blokhin, Darren H. Wakefield, David B. Rozema, David L. Lewis, Eric A. Kitas, Guenther Ott, Hans Martin Mueller, Ingo Roehl, Jeffrey C. Carlson, Jon A. Wolff, Jonathan D. Benson, Kerstin Jahn-Hofmann, Peter Mohr, Philipp Hadwiger, Torsten Hoffmann
Принадлежит: Arrowhead Madison Inc

The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.

Подробнее
Номер записи: 39
05-07-2012 дата публикации

Process for the identification of compounds for treating cancer

Номер: US20120172581A1
Автор: Damià TORMO CARULLA, María Soledad Soengas González
Принадлежит: Centro Nacional de Investigaciones Oncologicas CNIO

Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer.

Подробнее
Номер записи: 40
12-07-2012 дата публикации

Methods of optimizing disease treatment

Номер: US20120177632A1
Автор: Makoto Inoue, Mari L. Shinohara
Принадлежит: Duke University

Provided are methods for optimizing treatment of an autoimmune disease in a subject, methods for identifying and/or selecting a compound as a therapeutic for an autoimmune disease, methods of identifying a patient that is responsive to IFN-β therapy, and methods for identifying an agent that inhibits NLRP 3 inflammasome activity.

Подробнее
Номер записи: 41
12-07-2012 дата публикации

Inhibition of nfk-b mediated virus replication with specific oligosaccharides

Номер: US20120178671A1
Автор: Belinda Van't Land Potappel, Benjamin Berkhout, Francina Jeannette Dijk, Klaske Van Norren
Принадлежит: Nutricia NV

The inventors surprisingly found that specific oligosaccharides are capable of inhibiting viral replication through inhibiting NF-κB activation. The invention thus pertains to a composition comprising pectin (in the form of digalacturonic acid, trigalacturonic acid, polygalacturonic acid), Arabinoxylan from rice bran, β-glucan from bakers yeast, D-Ribose or mixtures there-of for inhibiting viral replication in a mammal with a viral disease.

Подробнее
Номер записи: 42
19-07-2012 дата публикации

Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases

Номер: US20120183593A1
Автор: Clyde Schultz
Принадлежит: DirectContact LLC

This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concentrations of compounds, e.g., from eye drops.

Подробнее
Номер записи: 43
26-07-2012 дата публикации

Cyanocobalamin low viscosity aqueous formulations for intranasal delivery

Номер: US20120190640A1
Автор: Anthony P. Sileno, Peter C. Aprile, Steven C. Quay, Zenaida O. Go
Принадлежит: Par Pharmaceuticals Inc

A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering, intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

Подробнее
Номер записи: 44
02-08-2012 дата публикации

Kits and improved compositions for treating lower urinary tract disorders

Номер: US20120196830A1
Автор: C. Lowell Parsons
Принадлежит: Individual

Superior buffered formulations and their kits for treating lower urinary tract symptoms and disorders are provided in the invention. In particular superior buffered formulations have demonstrated improvement for treating lower urinary tract symptoms of patients experiencing severe pain and/or urgency of the bladder and associated areas of the lower urinary tract.

Подробнее
Номер записи: 45
02-08-2012 дата публикации

PREVENTING ISLET INFLAMMATION AND DYSFUNCTION AND MAINTAINING PROPER GLUCOSE LEVELS BY CONTROLLING eIF5A AND ITS HYPUSINATION

Номер: US20120196918A1
Автор: Bernhard Maier, Raghavendra G. Mirmira
Принадлежит: Indiana University Research And Technology Corp

Pancreatic islet dysfunction, in both type 1 and type 2 diabetes results, in part, from cytokine-mediated inflammation leading to iNOS generation and the death of pancreatic islets. The production of pro-inflammatory cytokines involved in the generation of iNOS is facilitated by the availability of the hypusine-containing translational factor eIF5A, necessary for the maturation of antigen-presenting cells. Treatment with agents capable of interfering with the mRNA translating iNOS or with agents that can interfere with the hypusination of eIF5A, prevents the death of islets, lowers blood glucose levels, avoids insulin resistance, and generally avoids the inflammatory response in islets associated with type 1 and type 2 diabetes.

Подробнее
Номер записи: 46
23-08-2012 дата публикации

Diagnostic and Therapeutic Uses for B Cell Maturation Antigen

Номер: US20120213768A1
Автор: Gérard ZURAWSKI, Jacques F. Banchereau, Maria Virginia Pascual, Sangkon Oh
Принадлежит: BAYLOR RESEARCH INSTITUTE

Biomarkers and therapies against autoimmune diseases, including systemic lupus erythematosus (SLE) are described herein. The present invention is based on the discovery of B cell maturation antigen (BCMA) and BCMA variant expression on SLE monocytes that can be directly associated with disease activity. The findings of the present invention enable the design of monoclonal antibodies or recombinant proteins that can block BCMA and BCMA variants as well as BCMA-bound APRIL.

Подробнее
Номер записи: 47
23-08-2012 дата публикации

Methods of treating a subject and related particles, polymers and compositions

Номер: US20120213854A1
Автор: Oliver S. Fetzer
Принадлежит: Individual

Described herein are methods for treating a subject with combinations of polymer-agent particles and cyclodextrin polymer agent conjugates. The methods herein may be used to treat subjects identified with cancer, cardiovascular disorders, autoimmune disorders, or inflammatory disorders. Also described herein are compositions, dosage forms, and kits comprising polymer-agent particles and cyclodextrin polymer agent conjugates.

Подробнее
Номер записи: 48
23-08-2012 дата публикации

Methods for Diagnosing Colon Cancer Using MicroRNAs

Номер: US20120214694A1
Автор: Carlo M. Croce, George A. Calin, Stefano Volinia
Принадлежит: Ohio State University

The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis.

Подробнее
Номер записи: 49
23-08-2012 дата публикации

Modified L-Nucleic Acid

Номер: US20120214868A1
Автор: Bernd Eschgfäller, Christian Lange, Sven Klussmann
Принадлежит: NOXXON PHARMA AG

A modified L-nucleic acid, containing an L-nucleic acid part conjugated to a non-L-nucleic acid part is described. The conjugate has extended retention time in and demonstrates a delayed elimination from an organism.

Подробнее
Номер записи: 50
30-08-2012 дата публикации

Modified double-stranded polynucleotide

Номер: US20120220649A1
Автор: Makoto Koizumi, Yasuhide Hirota
Принадлежит: Daiichi Sankyo Co Ltd

The present invention provides a double-stranded polynucleotide having a sense strand polynucleotide consisting of a nucleotide sequence complementary to a target sequence in a target gene, and an antisense strand polynucleotide having a nucleotide sequence complementary to the sense strand polynucleotide, wherein an aryl or heteroaryl compound is bound to a phosphate group at the 5′-end of the antisense strand polynucleotide.

Подробнее
Номер записи: 51
30-08-2012 дата публикации

Composition comprising rna derived from lactic acid bacterium as effective component

Номер: US20120220760A1
Автор: Kazunari Ushida, Ryo Inoue, Takumi Watanabe
Принадлежит: Combi Corp, Kyoto Prefectural Public Univ Corp

A composition has an immunomodulation action, and comprises an RNA derived from a lactic acid bacterium as an effective component. Alternatively, a composition has a cytokine production-modulating action, and includes an RNA derived from a lactic acid bacterium as an effective component.

Подробнее
Номер записи: 52
30-08-2012 дата публикации

Ophthalmic Solutions

Номер: US20120220961A1
Автор: Fu-Pao Tsao
Принадлежит: Individual

An ophthalmic solution comprising a hydrogen peroxide source in an amount sufficient to result in between about 0.001% and about 0.01% by weight stabilized hydrogen peroxide in said formulation as a preservative, one or more ocularly-compatible hydrogen peroxide stabilizers, hydroxypropylmethylcellulose and sodium carboxymethylcellulose, as well as pharmaceutical compositions comprising such solutions, are provided.

Подробнее
Номер записи: 53
13-09-2012 дата публикации

Compositions and methods for modulating circadian synchronization

Номер: US20120230978A1
Автор: Gregor Eichele, Henrik Oster, Silke Kiessling
Принадлежит: Max Planck Gesellschaft zur Foerderung der Wissenschaften eV

The present invention relates to a modulator of glucocorticoid biosynthesis, degradation and/or receptor activation for use in preventing or treating symptoms and/or diseases associated with jet lag. The compositions of the invention may be used as a lead compound for developing a drug for preventing or treating symptoms and/or diseases associated with jet lag. The invention relates to the discovery that administration of the modulator(s) to a subject results in a directional change of the time point of maximum amounts of glucocorticoids in the subject as compared to the time point of maximum amounts of glucocorticoids in a subject not treated with the modulator(s).

Подробнее
Номер записи: 54
13-09-2012 дата публикации

Method to reduce the symptoms of heartburn and gastro-oesophageal reflux disease (gerd) by specific polysaccharides

Номер: US20120231078A1
Автор: Blaine G. Sudom, Calvin T. Kelly, Maria Anna Verbruggen
Принадлежит: Frutarom Netherlands BV

The invention is directed to the use of a specific group of polysaccharides for reducing the symptoms of heartburn and gastroesophageal reflux isease. In addition, a pharmaceutical preparation is provided comprising a specific group of polysaccharides having a high hydration rate, a high viscosity, and a high stability at low pH. Such a preparation is particularly effective in reducing the symptoms of heartburn and/or gastro-oesophageal reflux disease, particularly when consumed in dry form.

Подробнее
Номер записи: 55
20-09-2012 дата публикации

Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement

Номер: US20120237515A1
Автор: Leonard Bell, Russell P. Rother
Принадлежит: Alexion Pharmaceuticals Inc

Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.

Подробнее
Номер записи: 56
20-09-2012 дата публикации

Antithrombotic dual inhibitors comprising a biotin residue

Номер: US20120238512A1
Автор: Constant Adriaan Anton Van Boeckel, Martin De Kort
Принадлежит: MSD Oss BV

The present invention relates compounds of the formula (I) oligosaccharide-spacer-A (I), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa activity per se; the spacer is an essentially pharmacologically inactive flexible linking residue having a chain length of 10 to 70 atoms; A is the residue —CH[NH—SO 2 —R 1 ] [CO—NR 2 —CH(4-benzamidine)-CO—NR 3 R 4 ], wherein R1 is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (iso)quinolinyl, tetrahydro(iso)quinolinyl, 3,4-dihydro-1H-isoquinolinyl, chromanyl or the camphor group, which groups may optionally be substituted with one or more substituents selected from (1-8C)alkyl or (1-8C)alkoxy; and wherein R 2 and R 3 are independently H or (1-8C)alkyl; R 4 is (-8C)alkyl or (3-8C)cycloalkyl; or R 3 and R 4 together with the nitrogen atom to which they are bonded are a nonaromatic (4-8)membered ring optionally containing another heteroatom, the ring optionally being substituted with (1-8C)alkyl or SO2-(I-8C)alkyl; or a pharmaceutically acceptable salt thereof a prodrug or solvate thereof; wherein the compound of formula I further comprises at least one covalent bond with a biotin residue or an analogue thereof. The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombosis or other thrombin-related diseases. The antithrombotic activity of the compound of this invention can be neutralized in case of emergency upon administration of avidin, streptavidin and analogues thereof having high biotin affinity.

Подробнее
Номер записи: 57
27-09-2012 дата публикации

Tusc2 therapies

Номер: US20120244209A1
Автор: Charles Lu, David Stewart, Ignacio I. Wistuba, Jack A. Roth, Maria I. NUNEZ, Shaoyu YAN
Принадлежит: University of Texas System

A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.

Подробнее
Номер записи: 58
04-10-2012 дата публикации

Method of therapy and diagnosis of atherosclerosis

Номер: US20120252867A1
Автор: Ching-Yu Hu, I-Chung Hsieh, Ku-Chugn Chen, Suh-Hang Juo
Принадлежит: KAOHSIUNG MEDICAL UNIVERSITY

There is provided a method of therapy of atherosclerosis, by providing microRNA let-7g, an analogue thereof or modified let-7g to organisms to inhibit the expression of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), and the binding of LOX-1 and oxidized low-density lipoprotein (oxLDL), so as to block the pathogenesis of atherosclerosis. Also, a method of diagnosis of atherosclerosis comprises determining the levels of microRNA let-7g in serum or plasma samples of organisms, in which the levels of microRNA let-7g is estimated in individuals with atherosclerosis as compared to individuals without atherosclerosis.

Подробнее
Номер записи: 59
11-10-2012 дата публикации

Compositions for Controlling Varroa Mites in Bees

Номер: US20120258646A1
Автор: Eyal Ben-Chanoch, Eyal Maori, Gal Yarden, Haim Kalev, Ilan Sela, Sharoni Shafir, Yael Garbian
Принадлежит: Beeologics Inc, Yissum Research Development Co of Hebrew University of Jerusalem

An isolated nucleic acid agent is disclosed comprising a nucleic acid sequence which downregulates expression of a gene product of a Varroa destructor mite. Compositions comprising same and uses thereof are also disclosed.

Подробнее
Номер записи: 60
18-10-2012 дата публикации

Reversible platelet inhibition

Номер: US20120264815A1
Автор: Bruce A. Sullenger, Nanette Que-Gewirth, Sabah Oney, Shahid Nimjee
Принадлежит: Duke University

The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.

Подробнее
Номер записи: 61
25-10-2012 дата публикации

Nutritional composition for promoting gut microbiota balance and health

Номер: US20120269865A1
Автор: Clara Lucia Garcia Rodenas, Claudia Roessle, Douglas Richard Bolster, Florence Rochat, Jalil Benyacoub, Jennifer Rae Mager, Julie Ann Swanson, Norman Alan Greenberg, Zamzam (Fariba) Roughead
Принадлежит: Nestec SA

The present disclosure relates to nutritional compositions comprising a fructo-oligosaccharide (FOS) in an amount of 35 to 44% by weight; a polysaccharide that is not a partially hydrolyzed guar gum such as, for example, an arabinogalactan in an amount of 50% to 38% by weight; and inulin in an amount of 12% to 24% by weight. The FOS and the polysaccharide may be present in a weight ratio of about 1:1. More specifically, the FOS and inulin may be present in a weight ratio of about 7:3. Also provided are methods of promoting gut microbiota balance and health. The methods include administering an effective amount of the nutritional composition to patients in need of same.

Подробнее
Номер записи: 62
25-10-2012 дата публикации

Antiangiogenic Agent and Method for Inhibition of Angiogenesis

Номер: US20120270922A1
Автор: Fumitaka Muramatsu, Hiroyasu Kidoya, Nobuyuki Takakura
Принадлежит: Osaka University NUC

This invention provides an antiangiogenic agent having a higher treatment effect than those of conventional antiangiogenic agents, and a method for inhibiting angiogenesis using the same. An antiangiogenic agent comprising at least one miRNA type selected from the group consisting of miRNAs, pre-miRNAs, and pri-miRNAs, each having a miRNA activity on VE-cadherin.

Подробнее
Номер записи: 63
08-11-2012 дата публикации

Production of closed linear dna

Номер: US20120282283A1
Автор: Vanessa Hill
Принадлежит: Individual

An in vitro process for the production of closed linear deoxyribonucleic acid (DNA) comprises (a) contacting a DNA template comprising at least one protelomerase target sequence with at least one DNA polymerase in the presence of one or more primers under conditions promoting amplification of said template; and (b) contacting amplified DNA produced in (a) with at least one protelomerase under conditions promoting production of closed linear DNA. A kit provides components necessary in the process.

Подробнее
Номер записи: 64
08-11-2012 дата публикации

Wound Dressings Containing Complexes of Transition Metals and Alginate for Elastase-Sequestering

Номер: US20120282321A1
Автор: Kelman I. Cohen, Yousef Mohajer
Принадлежит: Individual

Transition metal (e.g., silver and copper) derivatized phosphorylated polysaccharides (cellulose, starch, gauze) provide antimicrobial and elastase sequestration properties to wound dressings, and the wound dressing have enhanced water sorption and elastase sequestration when used with alginates. Wound dressings with alginates (e.g., silver alginate, crosslinked alginates, etc.) provide enhanced wound fluid absorption as well as elastase sequestration.

Подробнее
Номер записи: 65
08-11-2012 дата публикации

Phosphate-binding magnesium salts and uses thereof

Номер: US20120282352A1
Автор: Charles E. Day, Robert L. Lewis
Принадлежит: Cypress Pharmaceuticals Inc

The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.

Подробнее
Номер записи: 66
08-11-2012 дата публикации

Inhibitors of Atypical Protein Kinase C and Their Use in Treating Hedgehog Pathway-Dependent Cancers

Номер: US20120283194A1
Автор: Anthony Oro, Scott X. Atwood
Принадлежит: Leland Stanford Junior University

Methods and compositions are provided for modulating Hedgehog (Hh) pathway signaling in a cell. Aspects of the methods include methods for inhibiting Hh pathway-promoted cancer proliferation and/or metastasis that is promoted by Hh pathway signaling, methods for treating cancers promoted by Hh pathway signaling, and methods for screening candidate agents for the ability to treat a cancer promoted by Hh pathway signaling. In addition, reagents and kits thereof that find use in practicing the subject methods are provided.

Подробнее
Номер записи: 67
08-11-2012 дата публикации

Use of polysaccharides for treating stress and anxiety

Номер: US20120283212A1
Автор: Daniel Wils, Laëtitia Guerin-Deremaux
Принадлежит: Roquette Freres SA

The present invention relates to a composition including a mix of a polysaccharides having: 15% to 50% of glucoside linkages 1-6; a reducing sugar content of less than 20%; a polymolecularity index of less than 5; an average molecular weight with number Mn of less than 4500 g/mole and at least one active agent for treating stress, anxiety and depressive behaviour, sleep disorders, obsessive-compulsive disorder, bulimia and epilepsy in humans or animals. The present invention also relates to the use of the polysaccharide for treating stress, anxiety or depressive behaviour, sleep disorders, obsessive-compulsive disorder, bulimia and epilepsy in humans or animals.

Подробнее
Номер записи: 68
08-11-2012 дата публикации

Computationally designed inhibitors of amyloidosis

Номер: US20120283409A1
Автор: Peter Law, Valerie Daggett
Принадлежит: UNIVERSITY OF WASHINGTON

Embodiments of the present invention include methods and systems for designing inhibitors of amyloidosis in humans, domesticated animals, and wild animals as well as inhibitors of amyloidosis designed by the methods and systems. Methods and systems for designing inhibitors of amyloidosis are largely computational, in nature, and are directed to designing various types of polymers, small-molecule organic compounds, organometallic compounds, or non-chemical physical processes that can target the extended-α-strand and α-sheet regions of amyloidogenic protein and polypeptide intermediates in order to prevent aggregation of those intermediates into protofibrils and fibrils that, in turn, recruit additional native-conformation proteins and polypeptides into amyloidogenic intermediates and that additionally aggregate to form higher-order structures, such as plaques observed in the brains of patients suffering from the various spongiform encephalopathies.

Подробнее
Номер записи: 69
15-11-2012 дата публикации

Therapeutic compositions and methods

Номер: US20120288495A1
Автор: John P. Vasilakos
Принадлежит: Biothera Inc

Methods relating to treating conditions that do not respond well to EGF-r antagonist therapies are disclosed. Generally, the methods include administering to a subject a composition that includes a β-glucan and, as either a second composition or a second component of the composition, either antibody that binds to at least one antigen specific to the KRAS-mutated cells and/or an EGF-r antagonist.

Подробнее
Номер записи: 70
15-11-2012 дата публикации

SDF-1 Delivery For Treating Ischemic Tissue

Номер: US20120289585A1
Автор: Joseph Pastore, Marc S. Penn, Rahul Aras, Timothy J. Miller
Принадлежит: Joseph Pastore, Miller Timothy J, Penn Marc S, Rahul Aras

A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification.

Подробнее
Номер записи: 71
22-11-2012 дата публикации

Novel Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds

Номер: US20120295832A1
Автор: Andrea Schuster, Anke Geick, Carla Alexandra Hernandez Prata, Ludger Markus Ickenstein, Philipp Hadwiger, Rainer Constien, Timo Weide, Torsten Haneke
Принадлежит: Arrowhead Research Corp

The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.

Подробнее
Номер записи: 72
29-11-2012 дата публикации

Immunostimulating Agent and Method for Production Thereof

Номер: US20120301505A1
Автор: Kazuya Iwai, Keiko Furuya, Michihiro Takagi, Nanaka Gotoda, Takemi Ueda
Принадлежит: Individual

The object is to provide: a safe immunomodulating agent which can be used as a pharmaceutical or a food material; a method for production of the immunomodulating agent; and a novel application of a coffee extract residue. Disclosed is an immunomodulating agent comprising a coffee extract as an active ingredient. Preferably, the coffee extract is an extract containing arabinogalactan. The immunomodulating effect of the immunomodulating agent relies on the promotion of the proliferation of an immunocompetent cell such as a macrophage. The immunocompetent cell is preferably any one selected from a macrophage like strain RAW264 or J774.1, a murine splenocyte, a murine peritoneal macrophage and a murine dendrocyte. A composition containing the immunomodulating agent can be used as a composition such as a pharmaceutical composition, a food composition and a cosmetic composition.

Подробнее
Номер записи: 73
29-11-2012 дата публикации

Conjugates, particles, compositions, and related methods

Номер: US20120302622A1
Автор: Donald E. Bergstrom, Jungyeon Hwang, Oliver S. Fetzer, Patrick Lim Soo, Pei-Sze Ng, Scott Eliasof, Sonke Svenson
Принадлежит: Cerulean Pharma Inc

Particles and conjugates for delivering nucleic acid agents. Compositions containing the particles, the conjugates, or both. Methods of using the particles, the conjugates, and the compositions.

Подробнее
Номер записи: 74
06-12-2012 дата публикации

Use of bacterial polysaccharides for biofilm inhibition

Номер: US20120308632A1
Автор: Jaione Valle, Jean-Marc Ghigo, Sandra Da Re
Принадлежит: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Institut Pasteur de Lille

A method comprises preventing or inhibiting bacterial adhesion and/or bacterial biofilm development by treating a substrate with a composition of a soluble group II capsular polysaccharide obtained from a bacterial strain.

Подробнее
Номер записи: 75
13-12-2012 дата публикации

Zwitterionic immunomodulators for the teatment of asthma and allergy

Номер: US20120315264A1
Автор: Arthur O. Tzianabos, Dennis L. Kasper
Принадлежит: Brigham and Womens Hospital Inc

Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain T regulatory (Treg) cells and to exert immunosuppressive effects in vitro and in vivo.

Подробнее
Номер записи: 76
13-12-2012 дата публикации

Treatment of renal injury

Номер: US20120315281A1
Автор: Alaa S. Awad
Принадлежит: PENN STATE RESEARCH FOUNDATION

Methods for the treatment of renal injury include the use of arginase inhibitors in the treatment and prevention of diabetic nephropathy, albuminuria and azotemia amongst others, and methods for identifying agents for the treatment of renal injury.

Подробнее
Номер записи: 77
13-12-2012 дата публикации

Composition for enhancing trail sensitivity comprising inhibitors for expression or activity of tip41 as a target gene of trail sensitizer

Номер: US20120315284A1
Автор: Cheol-hee Kim, Ga Hee Ha, Hyun-Taek Kim, In-Sung Song, Jeong-Min Kim, Jin-Man Kim, Joo Heon Kim, Nam-soon Kim, So-Young Jeong, Soo Young Jun
Принадлежит: Korea Research Institute of Bioscience and Biotechnology KRIBB

The present invention relates to a pharmaceutical composition, including inhibitors for expression or activity of TIP41 protein, for prevention and treatment of cancer. When the liver cancer cell lines, showing resistance to TRAIL, are treated with TIP41 siRNA and TRAIL, apoptosis is induced in cancer cell. The same effect is found in cases of lung cancer and colon cancer with resistance against TRAIL. Moreover, this induction of apoptosis by TIP41 siRNA and TRAIL was confirmed in tumor xenograft, which was injected with Huh7 liver cancer cells and then was subjected to TIP41 siRNA transfection and TRAIL treatment. In addition, it was confirmed through animal experiments in which the tumor size has reduced and apoptosis was induced by treatment with TIP41 siRNA and TRAIL. Of note, MKK7/JNK pathway was confirmed to mediate the apoptosis induced by the application of TIP41 siRNA and TRAIL. The apoptosis were verified to be caused by the activation of MKK7/JNK signaling pathway. Taken together, the present invention provide the strong evidence that the pharmaceutical composition, including inhibitors for TIP41 expression or activity can be used for cancer prevention and treatment as well as an anti-cancer adjuvant. Taken together, the pharmaceutical composition comprising inhibitors for expression or activity of TIP41 protein may be used for prevention and treatment of cancer or as an anti-cancer adjuvant.

Подробнее
Номер записи: 78
13-12-2012 дата публикации

combination for the treatment of osteoarthritis

Номер: US20120316217A1
Автор: Arborio Mella Isabella, Edoardo Carlo Maria Conti, Francesco Saverio Dioguardi, Franco Conti, Giovanni Federico Maria Conti
Принадлежит: Professional Dietetics SpA

The present invention relates to the use of a combination of glycine, proline, and optionally a natural or synthetic viscosity-controlling polymer, and/or lysine and/or leucine, to prepare a composition for the treatment of osteoarthritis.

Подробнее
Номер записи: 79
13-12-2012 дата публикации

Novel nucleic acid prodrugs and methods of use thereof

Номер: US20120316224A1
Автор: Gregory L. Verdine, Meena Meena, Naoki Iwamoto
Принадлежит: Ontorii Inc

Described herein are nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties. Also described herein are methods of making and using nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties.

Подробнее
Номер записи: 80
20-12-2012 дата публикации

Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene

Номер: US20120322853A1
Автор: Joseph Collard, Olga Khorkova Sherman
Принадлежит: Curna Inc

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Pancreatic Developmental gene, in particular, by targeting natural antisense polynucleotides of a Pancreatic Developmental gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Pancreatic Developmental genes.

Подробнее
Номер записи: 81
27-12-2012 дата публикации

Therapeutic Applications Targeting SARM1

Номер: US20120328629A1
Автор: Marc Freeman, Stephan Zuchner
Принадлежит: University of Massachusetts UMass, UNIVERSITY OF MIAMI

The present disclosure provides methods for reducing axonal and/or synaptic degradation in neurons by modulating sterile α/Armadillo/Toll-Interleukin receptor homology domain protein (SARM) activity and/or expression.

Подробнее
Номер записи: 82
27-12-2012 дата публикации

Therapeutic agent for fibroid lung

Номер: US20120328694A1
Автор: Rishu Takimoto, Yoshiro Niitsu
Принадлежит: Nitto Denko Corp

Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for fibroid lung, which utilized the carrier; and a preparation kit of the therapeutic agent.

Подробнее
Номер записи: 83
27-12-2012 дата публикации

Allergy inhibitor

Номер: US20120329752A1
Автор: Kengo Suzuki
Принадлежит: Euglena Co Ltd

The present invention provides an allergy inhibitor using the efficacy of amorphous paramylon which is a substance obtained by changing the crystalline structure of paramylon. The present invention relates to a substance for inhibiting allergic diseases. Amorphous paramylon of the present invention is an allergy inhibitor comprising amorphous paramylon which is obtained by amorphosizing crystalline paramylon derived from Euglena, and has a relative crystallinity of 20% or lower to the crystallinity of crystalline paramylon, determined by an X-ray diffractometry. This allergy inhibitor enables efficacious inhibition of allergic diseases such as atopic dermatitis, pollinosis, and the like.

Подробнее
Номер записи: 84
03-01-2013 дата публикации

Compositions and Methods for Inhibiting Gene Expression of Hepatitis B Virus

Номер: US20130005793A1
Автор: Daniel J. Chin, Jochen Deckert, Markus Hossbach, Matthias John
Принадлежит: Arrowhead Research Corp

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Hepatitis B Virus gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Hepatitis B Virus infection using said pharmaceutical composition; and methods for inhibiting the expression of a Hepatitis B Virus gene in a cell.

Подробнее
Номер записи: 85
03-01-2013 дата публикации

Anti-allergic agent

Номер: US20130005959A1
Автор: Aiko Shojo, Mamiko Kohno, Shinichi Kitamura
Принадлежит: Morishita Jintan Co Ltd

According to the present invention, an anti-allergic agent is provided which includes a polysaccharide comprising galactose, glucose and rhamnose as constituents, or includes a microorganism belonging to a genus Bifidobacterium and extracellularly producing the polysaccharide. The anti-allergic agent of the present invention can be used in oral compositions and compositions for external application, and is suitable for use in products such as food products, pharmaceutical products, and cosmetics.

Подробнее
Номер записи: 86
17-01-2013 дата публикации

Composition, and Method of Using the Composition, Effective for Minimizing the Harmful Effects Associated with Individuals Suffering from Alcohol Intoxication

Номер: US20130017276A1
Автор: Gregory Blackman
Принадлежит: BURN-OFF FORMALLY KNOWN AS SOBERUP LLC LLC

The present invention relates to a composition, and methods of using the composition, for minimizing the harmful effects associated with alcohol consumption. The composition includes a plurality of ingredients, which when combined, have the unexpected effect of increasing one or more metabolic pathways in the individual. As the metabolic rate is increased, alcohol is burned off, or utilized as energy source, and occurs at a considerably much faster rate than under normal physiological means. It is believed that the composition may have an effect on the brain causing it to increase metabolic rates. By administering the composition to an inebriated individual, the rate at which a person sobers up, occurs at a faster rate than would occur under normal physiological time frames.

Подробнее
Номер записи: 87
07-02-2013 дата публикации

Use of the modified polysaccharides for heparin neutralization

Номер: US20130034516A1
Автор: Kamil Kaminski, Krzysztof Szczubialka, Maria Nowakowska
Принадлежит: UNIWERSYTET JAGIELLONSKI

The subject of the invention is the use of cationically modified polysaccharides, except for chitosan, for direct neutralization of heparin in blood and physiological fluids in a mammal. Cationic modification of the polysaccharides is achieved using compound containing cationic ammonium groups and/or the polysaccharides are grafted with a polymer containing amine and/or ammonium groups.

Подробнее
Номер записи: 88
07-02-2013 дата публикации

Mitochondrial enhancement of cells

Номер: US20130034527A1
Автор: Lowell L. Wood, Roderick A. Hyde
Принадлежит: SEARETE LLC

Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells to at least one biological tissue.

Подробнее
Номер записи: 89
07-02-2013 дата публикации

Lipid formulated dsrna targeting the pcsk9 gene

Номер: US20130035371A1
Автор: Akin Akinc, Gregory Hinkle, Kevin Fitzgerald, Stuart Milstein
Принадлежит: Individual

This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene.

Подробнее
Номер записи: 90
14-02-2013 дата публикации

Aptamer to fgf2 and use thereof

Номер: US20130039855A1
Автор: Akira Ishiguro, Maiko Sakamoto, Yoshikazu Nakamura
Принадлежит: Ribomic Inc

Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.

Подробнее
Номер записи: 91
14-02-2013 дата публикации

Mir-150 for the treatment of blood disorders

Номер: US20130039895A1
Автор: Benjamin Ebert, David Scadden, Jun Lu, Shangqin Guo, Todd Golub
Принадлежит: Dana Farber Cancer Institute Inc, General Hospital Corp, Massachusetts Institute of Technology

The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.

Подробнее
Номер записи: 92
14-02-2013 дата публикации

Biomarker for sensitivity to therapy with a notch inhibitor

Номер: US20130039930A1
Автор: Andrey Anisimov, Kari Alitalo, Masahiro Yamamoto
Принадлежит: Vegenics Pty Ltd

Described herein are materials and methods for identifying subjects that would benefit from Notch-targeted therapy.

Подробнее
Номер записи: 93
14-02-2013 дата публикации

Immunomodulating compounds and related compositions and methods

Номер: US20130039949A1
Автор: Dennis L. Kasper, June L. Round, Ryan Michael O'connell, Sarkis Mazmanian
Принадлежит: Individual

Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile.

Подробнее
Номер записи: 94
14-02-2013 дата публикации

Compositions and Methods for Preventing and Treating Cancer via Modulating UBE1L, ISG215 and/or UBP43

Номер: US20130041016A1
Автор: Bret C. Hassel, Ethan Dmitrovsky, Ian Pitha-Rowe, Sutisak Kitareewan
Принадлежит: Dartmouth College

Compositions and methods of using compositions that induce UBE1L or a ubiquitin-like protein ISG15, or inhibit a deconjugase UBP43 to degrade oncogenic proteins and enhance apoptosis of cancer (neoplastic) or pre-cancerous (pre-neoplastic) cells are provided. Methods for the prevention or treatment of cancer via administration of these compositions are also provided.

Подробнее
Номер записи: 95
14-02-2013 дата публикации

Method of treating acute myelogenous leukemia

Номер: US20130041018A1
Автор: Timothy S. PARDEE, William H. Gmeiner
Принадлежит: Individual

A method of treating acute myelogenous leukemia (AML) in a subject in need thereof is carried out by administering the subject an active compound in an amount effective to treat the leukemia. The active compound comprises FdUMP[10] or a pharmaceutically acceptable salt thereof.

Подробнее
Номер записи: 96
21-02-2013 дата публикации

Compositions and methods for the prevention of cardiovascular disease

Номер: US20130045193A1
Автор: Angel E. Gil, Jesus G. Gil, Michael J. Gonzalez
Принадлежит: Angel E. Gil, Jesus G. Gil, Michael J. Gonzalez

The present invention relates to compositions comprising vitamins, minerals and other nutrients and methods for using these compositions for nutritional supplementation to prevent and/or alleviate a patient from the occurrence or negative effects of cardiovascular disease. Specifically, the invention relates to compositions and methods of administering compositions comprising natural CoQ 10 , natural Omega-3 fatty acids, natural bioflavonoids, natural vitamin E, amino acids and derivatives thereof, minerals, extra virgin olive oil, lecithin, B-complex vitamins, and antioxidants.

Подробнее
Номер записи: 97
21-02-2013 дата публикации

Immunostimulatory compositions and methods of use thereof

Номер: US20130045224A1
Автор: Ian Sims, Jonathan Mcdonald Counsell Stephens, Ralf Christian Schlothauer, Swapna Gannabathula
Принадлежит: Comvita New Zealand Ltd

Immunostimulatory compositions and methods of use are described to either enhance or diminish the immune stimulation effects of a honey or honey isolate by recognition of the presence of type II arabinogalactan compounds and utilising this knowledge to tailor the concentration of such compounds thereby adjusting the immune stimulation effects.

Подробнее
Номер записи: 98
28-02-2013 дата публикации

Methods of Inducing Tissue Regeneration

Номер: US20130052267A1
Автор: Helen M. Blau, Jason Pomerantz, Kostandin Pajcini
Принадлежит: Leland Stanford Junior University

Methods are provided for producing cells within a lineage (lineage restricted cells) from post-mitotic differentiated cells of the same lineage ex vivo and in vivo, and for treating a subject in need of tissue regeneration therapy by employing these lineage-restricted cells. In addition, the production of lineage restricted cells from postmitotic tissues derived from patients with diseases allows for a characterization of pathways that have gone awry in these diseases and for screening of drugs that will ameliorate or correct the defects as a means of novel drug discovery. Also provided are kits for performing these methods.

Подробнее
Номер записи: 99
07-03-2013 дата публикации

Use of pkc-iota inhibitors for the treatment of glioma

Номер: US20130058932A1
Автор: Mildred E. Acevedo-Duncan
Принадлежит: UNIVERSITY OF SOUTH FLORIDA, US Department of Veterans Affairs VA

The present invention pertains to use of PKC-iota inhibitors for treatment of glioma. In a specific embodiment, the treatment method comprises administering ICA-1 or a salt thereof to a subject with glioma. In another embodiment, the treatment method comprises contacting glioma cells with an effective amount of ICA-1 or a salt thereof.

Подробнее
Номер записи: 100